Osteoporosis Drugs Market Analysis 2024-2031 | Leading Companies, Pipeline Drugs & Outlook By DataM intelligence Report

The Global Osteoporosis Drugs Market reached US$ 14,066.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 19,336.6 million by 2031. The global osteoporosis drugs market is expected to exhibit a CAGR of 4.1% during the forecast period (2024-2031).

The Osteoporosis Drugs Market Report by DataM Intelligence offers comprehensive insights into the latest market trends, key growth drivers, and emerging challenges. Crafted to support smarter and faster decision-making, our reports blend in-depth data analysis with expert insights. At DataM Intelligence, we simplify complex market dynamics into actionable strategies-empowering businesses to remain competitive, scale confidently, and capitalize on the right opportunities in an ever-evolving landscape.

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/osteoporosis-drugs-market?kb

Osteoporosis Drugs Market Overview

Osteoporosis drugs are medications used to prevent, treat, or manage osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. These drugs work by either slowing down bone loss, increasing bone formation, or strengthening existing bone mass to reduce the risk of fractures, especially in the spine, hips, and wrists.

Research Methodology:

The global Osteoporosis Drugs Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Osteoporosis Drugs Market:

By Drug Class: Bisphosphonates, RANK Ligand Inhibitors, Selective Estrogen Receptor Modulators, Parathyroid Hormone Analog, Strontium, Calcitonin, Anti-Sclerostin, and Cathepsin K Inhibitor

By Product Type: Branded and Generics

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy and Other

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/osteoporosis-drugs-market?kb

List of the Key Players in the Osteoporosis Drugs Market:

F. Hoffmann-La Roche, Novartis AG, Merck & Co, Pfizer, Eli Lilly and Co. (Lilly), Amgen Inc., Radius Health, Teva Pharmaceutical Industries, GSK and AbbVie among others.

Industry Development:

In May 2023, Transcenta Holding Limited-a clinical-stage biopharmaceutical company with end-to-end capabilities in antibody-based therapeutic development-shared promising Phase I clinical data for TST002 (Blosozumab) in Chinese patients with low bone mineral density (BMD). A single intravenous dose of TST002 led to a significant increase in BMD by day 85 and was well tolerated across all tested doses.

Also in May 2023, new real-world evidence from a U.S. Medicare study involving nearly 500,000 postmenopausal women with osteoporosis revealed that Prolia (denosumab) was more effective at reducing fracture risk than oral alendronate, a commonly prescribed bisphosphonate. Over time, Prolia use was consistently associated with a notable reduction in fracture incidence.

Regional Analysis for Osteoporosis Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the global sales, production, consumption, imports, and exports in the Osteoporosis Drugs market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Osteoporosis Drugs industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Osteoporosis Drugs market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.